Skip to content

Better management of depression in cancer / Symptom Management Research Trials 3 Pilot

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16242820
Enrollment
20
Registered
2007-12-13
Start date
2007-12-03
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, major depressive disorder Cancer Cancer, major depressive disorder

Interventions

Usual care: The patients' general practitioner and oncologist will be informed of their diagnosis of MDD. Patients will then receive the usual clinical management of depression as currently practised

Sponsors

University of Edinburgh, Lothian Health Board, University Hospitals Division (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Have a diagnosis of cancer 2. Be aged 18 or over 3. Be under specialist oncology care 4. Have a predicted survival, estimated by their cancer specialist, of between three and twelve months 5. Have symptoms which meet the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for Major Depressive Disorder (MDD) (using the inclusive approach to diagnosis)

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent to participate 2. Episode of MDD is chronic (defined as a history of continuous depression for at least two years) 3. Judged to require urgent psychiatric care 4. Receiving active psychiatric or psychological treatment from specialist mental health services 5. Cognitive impairment or communication difficulties which are incompatible with the intervention 6. Known cerebral metastases 7. Unable to attend regularly for treatment sessions 8. Intervention is judged to be inappropriate due to a medical condition which requires alternative treatment 9. Intervention is judged to be inappropriate due to a psychiatric condition which requires alternative treatment (psychotic illness, bipolar affective disorder, obsessive compulsive disorder, substance abuse or dependence) 10. Participation in the trial is judged to be inappropriate on clinical grounds

Design outcomes

Primary

MeasureTime frame
Acceptability and feasibility of the trial procedures

Secondary

MeasureTime frame
The following data will be collected at baseline, 4, 8, 12, 16, 20 and 24 weeks: 1. Hopkin's Symptom Checklist Depression Scale (SCL-20) 2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 3. EuroQuol-5D 4. Satisfaction with depression care item

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026